GSK's Growth Drivers And Cost Containment Offset Pandemic Impact
Immunization Rates Returning To Pre-COVID Levels
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
You may also be interested in...
GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
Stockwatch: GSK And AstraZeneca Rush Into Each Other’s Back Yards
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.
GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.